Insider Selling: Gary Patou Sells 20,000 Shares of Pacira Pharmaceuticals Stock (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) Insider Gary Patou sold 20,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $100.26, for a total transaction of $2,005,200.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
A number of analysts have recently weighed in on PCRX shares. Analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals from $98.00 to $110.00 in a research note on Friday, August 1st. Separately, analysts at Canaccord Genuity raised their price target on shares of Pacira Pharmaceuticals to $114.00 in a research note on Friday, August 1st. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 1st. They now have a $109.00 price target on the stock, up previously from $86.00. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Pacira Pharmaceuticals has a consensus rating of “Buy” and an average target price of $104.68.
Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 1.58% during mid-day trading on Friday, hitting $101.13. The stock had a trading volume of 378,306 shares. Pacira Pharmaceuticals has a 52 week low of $35.13 and a 52 week high of $101.55. The stock has a 50-day moving average of $89.05 and a 200-day moving average of $76.34. The company’s market cap is $3.630 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, July 31st. The company reported $0.04 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.25. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $42.20 million. Pacira Pharmaceuticals’s revenue was up 175.2% compared to the same quarter last year. On average, analysts predict that Pacira Pharmaceuticals will post $-0.25 earnings per share for the current fiscal year.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Receive News & Ratings for Pacira Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.